Skip to main content
Kent Academic Repository

Inhibition of Endotoxin-Induced Uveitis by Methylprednisolone Acetate Nanosuspension in rabbits

Adibkia, Khosro, Omidi, Yadollah, Javadzadeh, Ali R., Barzegar-Jalali, Mohammad, Barar, Jaleh, Maleki, Nasrin, Mohammadi, Ghobad, Nokhodchi, Ali (2007) Inhibition of Endotoxin-Induced Uveitis by Methylprednisolone Acetate Nanosuspension in rabbits. Journal of Ocular Pharmacology and Therapeutics, 23 (5). pp. 421-432. ISSN 1080-7683. (doi:10.1089/jop.2007.0039) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:10060)

The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided.
Official URL:
http://dx.doi.org/10.1089/jop.2007.0039

Abstract

Purpose: In the current investigation, nanoformulations of methylprednisolone acetate(MPA) were formulated using Eudragit®RS100 to study their impacts on inhibition of

inflammatory symptoms in rabbits with endotoxin-induced uveitis (EIU).Methods: A modified quasi-emulsion solvent diffusion (QESD) technique was used for preparation of nanoparticles. The drug release profiles and physicochemical characteristics of the nanoformulations were studied by means of the X-ray crystallography, differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FT-IR). Particle size analysis yielded mean diameter of approximately 380, 460 and 580 (nm) for MPA-Eudragit®RS100 nanoparticles at the ratios of 1:2.5, 1:5 and 1:10, respectively. Major clinical symptoms of EIU (morphological changes, leukocytes numbers and protein levels within the aqueous humor) were examined.

Results: Upon the physicochemical characterizations, no crystal changes or chemical interactions were observed for MPA-Eudragit®RS100 nanoparticles. The 1:2.5 ratio of

drug-polymer resulted in the most controlled release of MPA. The in vivo examinations revealed that the endotoxin induced inflammation can be inhibited by the MPA-Eudragit®

RS100 nanosuspension more significantly than the microsuspension of MPA itself in the rabbits with EIU.

Conclusion: Based on our findings, we suggest that the MPA-Eudragit®RS100 nanosuspension may favor the localized controlled ocular delivery of MPA for prevention of inflammatory symptoms in ocular diseases.

Item Type: Article
DOI/Identification number: 10.1089/jop.2007.0039
Subjects: Q Science
Divisions: Divisions > Division of Natural Sciences > Medway School of Pharmacy
Depositing User: Ali Nokhodchi
Date Deposited: 10 Jul 2008 12:44 UTC
Last Modified: 05 Nov 2024 09:43 UTC
Resource URI: https://kar.kent.ac.uk/id/eprint/10060 (The current URI for this page, for reference purposes)

University of Kent Author Information

Nokhodchi, Ali.

Creator's ORCID:
CReDIT Contributor Roles:
  • Depositors only (login required):

Total unique views for this document in KAR since July 2020. For more details click on the image.